Skip to navigation Skip to main content Skip to footer

Approved Research

Risk of cardiovascular disease and all-cause/cause-specific mortality in patients with Non- alcoholic fatty liver disease.

Principal Investigator: Professor Jun Lyu
Approved Research ID: 62017
Approval date: December 2nd 2020

Lay summary

The aim of our project (estimated duration: 2 years) seeks to understand overall/cause-specific mortality based on the Non-alcoholic fatty liver disease(NAFLD) status of UK population and causal relationship of Non-alcoholic fatty liver disease(NAFLD) with cardiovascular disease, cancer and premature mortality.

Non-alcoholic fatty liver disease(NAFLD) has significantly increased in prevalence in parallel with increasing obesity and other components of metabolic syndrome. Conversely, those with obesity, metabolic syndrome, dyslipidemia, and diabetes have the greatest risk for Non-alcoholic fatty liver disease(NAFLD). The causal relationships of these diseases are controversial. Patients with Non-alcoholic fatty liver disease(NAFLD) have higher overall mortality, particularly from cardiovascular disease, cancer, and complications of liver diseases. Experimental evidence also illustrates that Non-alcoholic fatty liver disease(NAFLD) is associated with immune response regulation and prothrombotic state. Therefore, solid and thorough population researches of all-cause/cause-specific mortality in patients with Non-alcoholic fatty liver disease(NAFLD) are needed.

The potential to shed light on the underlying association of Non-alcoholic fatty liver disease(NAFLD) with other closely related diseases will stress the importance of population-based interventions in the UK. Such intervention will improve the prevention strategies for Non-alcoholic fatty liver disease(NAFLD) related diseases and reduce social financial burden on healthcare.

Scope extension:

current scope

1.Research question:

Non-alcoholic fatty liver disease(NAFLD) epidemiologically correlates with cardiovascular disease, cancer and metabolic syndrome, but the causal relationship is controversial.  Lifestyle intervention is the most important method to manage the Non-alcoholic fatty liver disease(NAFLD) patients. Solid and detailed researches are needed to evaluate the efficacy of individual or combined lifestyle intervention.  Most of studies focused on the occurrence of Non-alcoholic fatty liver disease(NAFLD) induced by risk factors, population researches evaluating how the risk factors affect the development of Non-alcoholic fatty liver disease(NAFLD) are limited. Experimental evidence illustrated that Non-alcoholic fatty liver disease(NAFLD) is associated with immune response regulation and prothrombotic state, but there need to discover further population evidence on this association.

  1. aims:

The aims of our project seeks to understand overall/cause-specific mortality based on the Non-alcoholic fatty liver disease(NAFLD) status of UK population and causal relationship of Non-alcoholic fatty liver disease(NAFLD) with cardiovascular disease, cancer and metabolic syndrome.

New scope

1.Research question:

It has become increasingly clear that certain CVD risks tend to cluster, or occur together. Metabolic sydrome(Mets) was a cluster of important cardiovascular disease(CVD) risk factors. This clustering of some risk factors and their shared responsiveness to lifestyle modifications suggests that they are not independent of one another and that they share underlying causes, mechanisms and features. Non-alcoholic fatty liver disease(NAFLD), pre-diabetes status and pre-hypertensive status were thought to be menifestation of Mets in different organs. It is important to clarify the importance and interactive association of those different manifestation of Mets for CVD mortality and all cause mortality based on population study.

2.aims:

The aim of our project seeks to understand causal relationship of different components of Mets with CVD and all cause mortality, further sheding

light of the interactive association of different manifestation of Mets, such as NAFLD, prediabetes status and pre-hypertension status